MedTrace Logo

A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni

NCT01054651 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2010-01-22

No results posted yet for this study

Summary

The purpose of this study is to determine the comparative efficacy of artesunate plus sulfamethoxypyrazine-pyrimethamine versus Praziquantel in the treatment of school children infected with S.mansoni in western Kenya.

Conditions

  • Schistosoma Mansoni

Interventions

DRUG

Artesunate+Sulfamethoxypyrazine/pyrimethamine

DRUG

Praziquantel

Sponsors & Collaborators

  • Dafra Pharma

    collaborator INDUSTRY

  • Kenya Medical Research Institute

    lead OTHER

Principal Investigators

  • Pauline N Mwinzi, PhD · Kenya Medical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Kenya

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01054651 on ClinicalTrials.gov